FDA highlights in ophthalmology: third quarter 2026

The third quarter of 2026 delivered some of the most closely watched retina approvals in years, a new entrant in the minimally invasive glaucoma surgery (MIGS) category, a regulatory designation that could accelerate a leading gene therapy candidate for geographic atrophy (GA), and the start of formal FDA review for a novel dual-mechanism glaucoma drop. Below is a roundup of the quarter's key regulatory actions, along with the developments still to watch as the year winds down.